TEVA enters its July 29 second-quarter earnings report having shed 7% over the past month to $30.81, with the stock down another 4% on the week. That recent softness stands in contrast to the analyst consensus, and the tension between where the Street sees fair value and where the market has taken the stock defines the central question heading into the print.
Options positioning offers no strong conviction signal either way. The put/call ratio of 0.37 is essentially flat with its 20-day average of 0.37, and the z-score of near zero confirms there is nothing unusual in how traders are hedging into the release. The ratio is well off its 52-week peak of 0.76, implying that defensive positioning is notably lighter than it has been at prior stress points. The borrow market echoes that indifference: availability is effectively unrestricted at over 2,300% of short interest, cost to borrow runs at a negligible 0.44%, and short shares have declined roughly 4% over the past month to around 32 million. The lending market signals no meaningful short squeeze risk, nor any unusual scramble to build bearish positions.
The bull case is built squarely on the gap between the current price and analyst targets. The Street consensus points to $40.90, implying more than 30% upside from Thursday's close, with seven buy ratings and no sells. Barclays and JP Morgan both raised targets following the prior quarterly print in late April, and BofA lifted its target to $42 in early April. The constructive argument centres on Teva's Emalex acquisition bolstering its generic drug franchise, ongoing debt reduction, and expanding neurology and immunology pipelines. Bears counter with a more immediate concern: inventory timing creates risk of a flat quarter before any recovery, while regulatory uncertainty, litigation exposure, and the pace of margin expansion all represent execution risk that the current multiple may not fully price. The trailing P/E at 11.6x and EV/EBITDA near 9.7x are undemanding, which is partly why analysts remain bullish — but the 90-day EPS momentum score in the low 30s percentile suggests forward estimates have not been moving in the right direction.
One institutional development worth noting: WCM Investment Management added over 26 million shares as of the most recent quarter, lifting its stake to 3.5% of shares outstanding — a material new conviction position from an active manager. Capital Research and Management also added 6.5 million shares in the same period. Against that, Rubric Capital trimmed by over 6 million shares. The pattern among recent earnings reactions gives modest historical context: TEVA jumped over 10% on the day after its late-April print and extended that gain to nearly 15% over the following five sessions, though the May release produced a much quieter 2% one-day move with minimal follow-through.
The July 29 print is therefore less a test of whether Teva's turnaround is on track and more about whether the Q2 numbers clear the inventory-timing overhang the bear case identifies — and whether management's forward commentary on margins and pipeline progress is strong enough to close the distance between $30 and the $40-plus target cluster the Street has assembled.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
